Mutational analysis of reverse transcriptase and surface proteins of patients with partial virological response during mono and combination antiviral therapies in genotype D chronic hepatitis B.
Result: N236T and compensatory mutation (A181T/P) were found to be between 3.2 and 6.4%, respectively (Table 2).
Hepatitis B virus rtA181T/sW172non-stop mutation may increase resistance fold to adefovir- and entecavir-resistant mutants compared to rtA181T/sW172* mutation.
Abstract: As the polymerase gene completely overlaps with the envelope (S) gene, HBV rtA181T mutation also carries sW172 mutations.
Abstract: In animal experiments, we were amazed to find that viral replication in rtA181T/sW172* mutant increased and maintained significantly longer than that in rtA181T/sW172L mutant, while no significant difference was observed between rtA181T/s PMID: 28139541
2016
The Indian journal of medical research
Result: VBT on ADV monotherapy was noted in eight patients (33.3%), rtA181T and rtN236T mutants were detected alone in 8.1 and 8.3 per cent in the conserved regions B and D of rt region of HBV polymerase gene, respectively.
Nucleos(t)ide analogues causes HBV S gene mutations and carcinogenesis.
PMID: 27919846
2016
Hepatobiliary & pancreatic diseases international
1Abstract: DATA SOURCES: PubMed and Web of Science were searched using terms: ""hepatitis B virus"", ""HBV drug resistance mutation"", ""HBV surface protein"", ""HBV truncation"", ""hepatocellular carcinoma"", ""rtA181T/sW172*"", ""rtM204I/sW196*"", ""rtV191I/sW182*"", and relevant articles published in English in the past decades were reviewed."
Abstract: RESULTS: The rtA181T/s
Hepatocarcinogenesis in transgenic mice carrying hepatitis B virus pre-S/S gene with the sW172* mutation.
Abstract: Hepatitis B virus (HBV) carrying the rtA181T/sW172* mutation conferred cross-resistance to adefovir and lamivudine.
Introduction: Clinical analysis showed that the rtA181T/sW172* mutation was associated with an increased risk of HCC in cirrhotic patients.
Introduction: In the present study, we aimed to provide transgenic mouse evidence for the increased oncogenicity of pre-S/S proteins carrying the rtA181T/s
Relationship between hepatitis B virus reverse transcriptase 181 mutation and S gene mutation in hepatitis B virus chronically infected patients.
PMID: 27894395
2016
Cellular and molecular biology (Noisy-le-Grand, France)
Abstract: rt
Abstract: Among 25 containing rtA181T/V mutation patients, 7 rtA181T mutation cases with sW172L, 6 rtA181T mutation cases with sW172*, 12 rtA181Vmutation cases with sL173F.
Abstract: Mutation sites of pre-existing and adefovir dipivoxil induced resistance were different (adefovir dipivoxil induced resistance mode is rtA181T/V, and pre-existing mode is the other).
Pre-existing mutations related to tenofovir in chronic hepatitis B patients with long-term nucleos(t)ide analogue drugs treatment by ultra-deep pyrosequencing.
Result: A wave of resistantance-associated variants was detected at 3 year, as the frequency of the rtA181T substitution rose from 1.91% to 54.23%.
Result: All treatment-naive patients carried rtA181V/T substitutions (ranging from 1.1% to 8.7%) and rtN236T substitutions (ranging from 1.4% to 6.1%).
Result: As shown in Figure 8B, this patient harbored the rtA181T (1.3%) and rtN236T (1.6%) substitutions at baseline, and other resistance mutations were present at low levels (<1%).
Result: At baseline, patient 2 harbored the rtA181T (4.7%), PMID: 27313669
2016
Experimental and therapeutic medicine
Result: ADV-resistant variant rtA181T then decreased and became undetected after 23 months of combination therapy.
Result: ADV-resistant variants rtA181 V/T and rtN236T went from being dominant at initiation of ADV-ETV combination to undetectable, during an average duration of combination therapy of 19.33 months (range, 11-24 months).
Result: During sequential monotherapy, the levels of LAM-resistant variants (rtM204I/V with or without rtL180 M) gradually decreased as treatment progressed, whereas ADV-resistant rtA181 V/T and
Delayed Reduction of Hepatitis B Viral Load and Dynamics of Adefovir-Resistant Variants during Adefovir plus Entecavir Combination Rescue Therapy.
PMID: 26005376
2015
International journal of medical sciences
Introduction: They include rtA181V/T and rtN236T.
Introduction: This may be attributed to an ADV-resistant variant, rtA181V/T, which is responsible for cross-resistance to LAM and ADV.
Discussion: This is mainly attributed to the ADV mutation, rtA181V/T, which is responsible for cross-resistance to LAM and ADV.
Microarray-based genotyping and detection of drug-resistant HBV mutations from 620 Chinese patients with chronic HBV infection.
PMID: 25982306
2015
The Brazilian journal of infectious diseases
Abstract: Of these, nine and eight patients carried lamivudine (LAM)-/telbivudine (LdT)-resistance mutations (rtL180M, rtM204I/V) and adefovir (ADV)-resistance mutations (rtA181T/V, rtN236T), respectively.
HBV mutation literature information.
PMID: 
2016
Electronic physician
Browser Board
Co-occurred Entities
Filtrator
ViMRT